Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients Enrolled in the Forte Trial (https://www.myeloma.org/videos/results-newly-diagnosed-transplant-eligible-multiple-myeloma-patients-enrolled-forte-trial)
What is the purpose of this study?
The aims of this analysis were the evaluation of (1) the rate of conversion from MRD-positivity (MRD-pos) to MRD-negativity (MRD-neg) with MFC and NGS during maintenance and (2) the impact on progression-free survival (PFS) and overall survival (OS) of MRD-neg with both techniques in different subgroups including different treatment arms.
In this video:
Dr. Stefania Oliva gives a report on the results of the FORTE trial on MRD via multiparameter flow cytometry (MFC) and next-generation sequencing (NGS) techniques. MRD was evaluated by these two techniques and the best technique between these two was evaluated.
Results:
The outcomes of patients who were MRD-NEG by MFC and NGS at 10-5 were similar, as well as those of patients with 1-year sustained MRD-NEG by MFC and NGS.
Conclusion:
The final outcome of MRD negative patients is superimposable regardless of treament. High degree of clinical concordance between MFC and NGS MRD.
ASH 2020: Abstract 491 (https://ash.confex.com/ash/2020/webprogram/Paper137351.html)
STEFANIA OLIVA, MD, PhD
Dr. Stefania Oliva isa member of the Myeloma Unit, Division of Hematology, University of Torino, Turin University Hospital Azienda Ospedaliero‐Universitaria Città della Salute e della Scienza di Torino.